Context. The use of targeted therapy at the end of life has not been well characterized.
Introduction
Our increased understanding of the molecular basis of cancer has resulted in an explosion in the number of targeted therapeutic options. 1, 2 Targeted agents include a vast array of monoclonal antibodies, tyrosine kinase inhibitors, and other biologics and are now being routinely used in patient care, with many more under development. 3 Most of these agents are given, with a palliative intent, to patients with advanced cancer.
The use of targeted therapy at the end of life has not been well characterized. Multiple studies have examined the use of chemotherapy among patients with far advanced disease. 4, 5 Chemotherapeutic agents are generally associated with significant toxicities and limited benefits when given to patients with poor performance status and/or survival. Thus, published literature considers the use of chemotherapy in the last two to four weeks of life a negative quality-of-care indicator. 6e8 To our knowledge, only two studies have examined the use of targeted agents at the end of life, one focusing on patients with lung cancer 9 and the other on patients admitted to an acute palliative care unit. 10 A better understanding of the frequency of targeted agent use at the end of life, and the factors associated with their use, would potentially allow us to improve the quality of end-of-life care. In this retrospective study, we determined the frequency and predictors of targeted agent use in the last 30 days of life.
Methods

Study Setting and Eligibility Criteria
The M. D. Anderson Cancer Center Institutional Review Board approved this study and waived the requirement of informed consent. All adult patients in the Houston area who died of advanced cancer between September 1, 2009 and February 28, 2010 and had contact with M. D. Anderson Cancer Center within the last three months of life were included in this study. Patients who transferred care to outside oncologists, relocated to another city, or who were lost to follow-up were excluded. These criteria were chosen so that all patients were either under the direct care of M. D. Anderson Cancer Center or referred to a local hospice, and we were able to reliably capture their information at the end of life.
11
Data Collection
We collected baseline demographics, including age, sex, race, marital status, cancer diagnosis, and date of advanced cancer diagnosis. Advanced cancer is defined as locally advanced, metastatic, or recurrent disease not amenable to local therapy for solid tumors; advanced stage disease for chronic leukemias and low-grade lymphomas; and recurrent disease for acute leukemias, high-grade lymphomas, and multiple myeloma.
Both chemotherapy and targeted agents, either standard and/or experimental regimens, are available for every tumor type at our institution. The medication name(s) and date of the last documented targeted or chemotherapeutic treatment received before death were retrieved from the electronic chart. Steroids and hormonal therapy were not examined.
Statistical Analysis
We summarized the baseline demographics using descriptive statistics, including means, medians, ranges, interquartile range (IQR), and frequencies. We compared the characteristics between patients who received targeted agents and those who did not receive targeted agents in the last 30 days of life using the t-test for continuous, normally distributed variables (e.g., Table 1 shows the baseline characteristics of the 816 decedents included in this study. Gastrointestinal and lung malignancies were the most common. The median interval between advanced cancer diagnosis and death was only 12 (IQR 5e25) months.
Results
Patient Characteristics
Targeted and Chemotherapeutic Agent Use at the End of Life
Three hundred thirty-four (39%) patients with advanced cancer received targeted agents and 533 (65%) patients received chemotherapy during the course of their illness. The median interval between the last treatment and death was 47 (IQR 21e97) days for targeted agents and 57 (IQR 26e118) days for chemotherapeutic agents. Table 2 . The use of targeted agents in the last 30 days of life was associated with chemotherapy use in the same period (P < 0.001). Forty-three (5%) patients received both chemotherapy and targeted agents in the last 30 days of life.
In the last 30 days of life, the median number of antineoplastic agents administered was one (IQR 1e1) for targeted agents, one (IQR 1e2) for chemotherapeutic agents, and one (IQR 1e2) for any chemotherapy and targeted therapy among patients who received the respective treatments. Table 3 shows the separate univariate analysis for patient characteristics associated with (Table 4) . In the univariate analysis, patients who were young, had hematologic malignancies, and a short interval between advanced cancer diagnosis and death were more likely to receive chemotherapy in the last 30 days of life (Table 3) . Multivariate regression analysis showed that hematologic malignancies and a short duration between advanced cancer diagnosis and death were independently associated with chemotherapy administration (Table 4) . In contrast, patients with head and neck, lung, genitourinary, gastrointestinal, and other malignancies (e.g., central nervous system, sarcoma, and thyroid) were less likely to receive chemotherapy at the end of life. Table 5 shows the median interval from last anticancer treatment to death by cancer type.
Factors Associated With Targeted and Chemotherapeutic Agent Use in the Last 30 Days of Life
Discussion
In this study, more than one in four patients received palliative systemic therapy within the last 30 days of life, and more than one in eight patients received targeted therapy during this period. Targeted agent use at the end of life was associated with younger age and hematologic and lung malignancies.
At our institution, targeted therapy was used almost as commonly as chemotherapy in the last 30 days of life, with a small proportion of patients receiving both. Our study had similar rates of patients receiving chemotherapy at the end of life relative to other studies using large population databases, although the interval between last chemotherapy and death was shorter in our cohort (median 57 days vs. >120 days). 6, 8, 12 This difference may be explained by the varying time periods, patient populations, and settings. Furthermore, unlike population studies, we painstakingly reviewed the charts to exclude patients who died without evidence of disease.
The decision to start or stop palliative systemic therapy is an intricate, technical, and often emotionally charged judgment, particularly when the patient is near the end of life. 13 It involves an educated estimation of the risks and benefits by the medical oncologist, guided by clinical evidence and various factors related to the disease, patients, physicians, and practice patterns. As shown in this study, the type of malignancy determines the spectrum of available cancer treatment options, which, in turn, dictates treatment utilization. In addition, the cancer's mutation profile allows oncologists to tailor therapy in the era of personalized medicine. Patients' wishes, prognosis, comorbidities, performance status, adherence, and social support are often taken into consideration in the decision-making process. Oncologists' decisions Although nausea and vomiting, myelosuppression, and alopecia generally occur less frequently than with chemotherapy, targeted agents are associated with many unique adverse effects, such as rashes, endocrine abnormalities, and electrolyte imbalances. 15 Folliculitis occurs in up to 80% of patients on epidermal growth factor receptor inhibitors, such as erlotinib and cetuximab, and can be associated with pain, pruritus, and disfigurement. 16, 17 Bevacizumab may infrequently cause life-threatening vascular catastrophes and impaired wound healing.
18e20 Everolimus is associated with significant mucositis and electrolyte abnormalities. 21 Sorafenib and sunitinib can both lead to severe fatigue, metabolic changes, and hypothyroidism. 22, 23 In addition to the adverse effects and potential complications requiring hospitalization, there are many less obvious risks to consider when prescribing targeted therapy at the end of life, including frequent hospital visits, invasive investigations, and the tremendous financial burden associated with cancer treatments and supportive care ( Table 2) . 24 Furthermore, the pursuit of life-prolonging therapy could potentially delay transition of care, diverting patients' precious time and energy to the pursuit of cancer treatments rather than planning ahead.
Palliative therapies are often prescribed with the intention of improving symptom control, sustaining hope, and prolonging survival. 25, 26 When a treatment is given in the last 30 days of life, the benefit is arguably negligible. However, it should be noted that clinicians often overestimate survival; 27, 28 thus, the use of life expectancy as a criteria for quality of care may be challenging. Instead, performance status has been clearly shown to be an important prognostic and predictive factor. 29 When a patient reaches an Eastern Cooperative Oncology Group performance status of 3 or more (or Karnofsky Performance Status of 40% or less), great caution should be exercised when prescribing palliative systemic therapies. This is the first study to examine predictors of targeted therapy use at the end of life. We found that hematologic malignancy was associated with targeted therapy use. This is not surprising given that patients with hematologic malignancies generally have a poor quality of end-of-life care. 8 Previous studies have shown that these patients are more likely to receive cytotoxic therapy at the end of life and to be admitted to and die in hospitals and intensive care units and less likely to be referred to palliative and hospice care. 10,30e32 The availability of novel targeted agents for leukemia and lymphoma probably contributed to our observation. For the same reason, erlotinib is often available to lung cancer patients at the end of life. Our findings are consistent with a small In contrast, patients with head and neck cancer, central nervous system tumors, and sarcoma were less likely than patients with other tumor types to receive targeted therapy, likely because of the relative lack of standard targeted therapy options for these cancers. We also found that younger patients were more likely to receive targeted therapy at the end of life, consistent with other studies demonstrating that they are generally managed more aggressively than older patients. 10 This study has several limitations. First, findings in this study are solely based on patients who seek care at our comprehensive cancer center. Our institution offers a wide array of therapeutic options, including numerous clinical trials of novel agents and a large Phase I experimental therapy program. Many patients come specifically to seek further cancer treatments when no standard therapies exist. Because the patient characteristics, practice patterns, and resource availability may differ from other oncology settings, further studies are needed to determine if our findings are generalizable. Second, in addition to the predictors identified above, several factors, such as patient preference, performance status, comorbidities, and clinician characteristics, may determine whether patients receive antineoplastic therapy at the end of life. We were unable to include these variables because they were not routinely documented. Prospective studies could examine these factors in further detail. Third, we did not capture information on treatment toxicities because they were often mixed with patients' underlying symptom burden. Fourth, we only included a short study period. Further studies are needed to examine the trends of targeted agent use at the end of life. Finally, by excluding patients who were not seen by our institution in the last three months of life, we could have inflated the proportion of patients who received chemotherapy or targeted agents at the end of life if these patients were less likely to seek aggressive treatments in the last three months. The opposite also may be true if many of these individuals decided to seek further treatments with their local oncologists after their last visit at our institution. Further studies are required to examine patients' treatment patterns in the community.
In summary, targeted agents were used as often as chemotherapy at the end of life, particularly among younger patients and those with hematologic and lung malignancies. The use of chemotherapy in the last days of life has been established as a quality of end-of-life care indicator. 7, 12 Our study raises the question whether targeted therapy also should be considered as another quality-of-care indicator. Given the increasing number of targeted therapeutic options and the growing number of clinical trials, we expect a sustained rise in the use of targeted agents at the end of life. Thus, we urgently need to develop guidelines on when to start and stop palliative systemic therapies for cancer patients with a limited life expectancy.
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